CN101843820B - Glucuronolactone-containing medicament for protecting liver and lowering transaminase - Google Patents

Glucuronolactone-containing medicament for protecting liver and lowering transaminase Download PDF

Info

Publication number
CN101843820B
CN101843820B CN2010101740151A CN201010174015A CN101843820B CN 101843820 B CN101843820 B CN 101843820B CN 2010101740151 A CN2010101740151 A CN 2010101740151A CN 201010174015 A CN201010174015 A CN 201010174015A CN 101843820 B CN101843820 B CN 101843820B
Authority
CN
China
Prior art keywords
hepatitis
chinese medicine
time
group
glucurolactone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010101740151A
Other languages
Chinese (zh)
Other versions
CN101843820A (en
Inventor
李国�
张大宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linyi High Tech Zone Jinlanling Labor Service Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2010101740151A priority Critical patent/CN101843820B/en
Publication of CN101843820A publication Critical patent/CN101843820A/en
Application granted granted Critical
Publication of CN101843820B publication Critical patent/CN101843820B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a synergistic medicinal composition containing glucuronolactone and traditional Chinese medicine extract and the application thereof in preparing medicaments for adjuvant treatment of hepatitis.

Description

The medicine that contains the liver protecting and ALT lowering of glucurolactone
Invention field
The present invention relates to the Pharmaceutical composition formed by glucurolactone and Chinese medicine extract, and the purposes of said composition in the medicine of preparation adjuvant treating hepatitis.
Background technology
Hepatitis has multiple sorting technique clinically, classifies as (1) nosetiology: viral hepatitis can be divided into five types is first, second, third, fourth, penta.(2) clinical classification can be divided into following a few type: 1. acute anicteric hepatitis, this is a modal type in the viral hepatitis, see with B-mode, third type, hepatitis D more, general this type of hepatitis clinical symptoms is less, and transaminase's elevated levels is lower, and Histological change is light, mortality rate is lower, but the course of disease can be delayed the long period, and " three is slow " characteristics are arranged, and morbidity is slow, recovery is slow, delay also slow (referring to the long meaning slowly); 2. acute icterohepatitis is less relatively compared with anicteric hepatitis, and the state of an illness is a self limiting often, and how good prognosis is, but minority can develop into hepatitis gravis; 3. chronic hepatitis: relevant experts in 1994 propose the name and the suggestion of chronic hepatitis again, with the cause of disease is the diagnosis name that chronic hepatitis is determined on the basis, simultaneously ordered grade scale, formulated standard by stages according to degree of hepatic fibrosis again according to the downright bad order of severity of hepatitis inflammation; 4. hepatitis gravis can be divided into acute heavy type, severe subacute and chronic heavy type again; 5. cholestatic hepatitis.
Wherein hepatitis B is caused by hepatitis B virus, serves as main a kind of infectious disease that also can cause multiple organ injury with the liver inflammatory lesion.China is the most popular country of hepatitis B, reaches more than 35% some local crowd infection rate, and be the most serious infectious disease of current harm people ' s health.According to investigations, China's hepatitis B patient is about 2,700 ten thousand, and annual New Development patient about 9,000,000.
The hepatitis B clinical manifestation is various, easily develops into chronic hepatitis and liver cirrhosis, and a few peoples finally develop into hepatocarcinoma.Hepatic fibrosis is the total pathological change of many chronic hepatopathy evolutions, and the damage of chronic, persistence is the prerequisite that hepatic fibrosis forms.Cause the factor of hepatic injury a lot,, hepatitis B, liver cirrhosis, take some drugs for a long time and can cause acute and chronic liver injury generally because of factors such as medicine, a large amount of ethanol, allergy cause acute liver damage.By reducing detrimental effect to liver function, can adjuvant treating hepatitis.
The medicine that is used for the treatment of the acute and chronic hepatic injury at present, commonly used have diammonium glycyrrhizinate, glucurolactone, a bifendate etc.These chemicalses generally have certain side effect, and cause that therapeutic effect at a specified future date is poor, problem such as Strain produces after drug resistance phenomenon, the drug withdrawal relapse rate height.
The curative effect of Chinese medicine hepatitis B is proved by a large amount of clinical trials.Chinese medicine all can be brought into play curative effect preferably at aspects such as antiviral, adjusting immunity of organisms, protection hepatocyte.But Chinese medicine preparation ubiquity onset at present is slow, needs problems such as life-time service.
Therefore, Western medicine and Chinese Medicine and Clavicular need be got up, i.e. synergism is played in Chinese medicine and western medicine combination, solves the problem that above-mentioned Western medicine and Chinese medicine exist in auxiliary treatment all kinds hepatitis separately, produces synergistic therapeutic effect simultaneously.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of glucurolactone and a kind of Chinese medicine extract, wherein prepares on the method basis of the Chinese medicine extract of said composition according to embodiment among the special CN1186064C of China, and is as follows:
With Rhizoma Polygoni Cuspidati 250g, Fructus Gardeniae 200g, Cortex Phellodendri 200g, Herba Reineckeae Carneae 100g, Rhizoma Belamcandae 100g, Radix Sophorae Flavescentis 200g, Radix Salviae Miltiorrhizae 400g decoct with water 3 times, and the 1st time 1.5 hours, the 2nd time 1 hour, the 3rd time 1 hour, merge 3 times decoction liquor, filter, being concentrated into relative density is the thick paste of 1.22-4.25 (25 ℃).
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in preparation auxiliary treatment all kinds hepatitis medicament.
This Chinese medicine the water extracted immersing paste is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong transaminase lowering effect, i.e. function for protecting liver and reducing enzyme activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemical liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the pharmacodynamics test of Pharmaceutical composition anti-liver injury of the present invention.
The test grouping:
1, normal control group: animal does not do any processing, and normal physiological saline is irritated stomach;
2, model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
3, pure Chinese drug-treated group: the water extracted immersing paste 0.98g/kg body weight as indicated above
4, glucurolactone group: the 10mg/kg body weight is irritated stomach
5, compositions group: 10mg/kg body weight glucurolactone+the water extracted immersing paste 0.98g/kg body weight mentioned above is irritated stomach.
Following table has shown the influence of each group to Mouse Liver function leading indicator GOT, GPT.
Group Number of animals GOT (active unit) GPT (active unit)
The normal control group 10 21.90±17.67 47.56±16.49
Model control group 10 248.75±75.59 310.12±60.89
Pure Chinese drug-treated group 10 181.65±60.79 241.85±59.08
The glucurolactone group 10 98.67±34.75 202.64±31.86
The compositions group 10 86.97±18.28 110.73±47.95
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, glucurolactone group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and glucurolactone group.Show that there are cooperative effect in glucurolactone and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio glucurolactone and Chinese medicine extract mentioned above at 1: 98.
Can produce the capsule that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio glucurolactone and Chinese medicine extract mentioned above at 1: 98.

Claims (2)

1. the Pharmaceutical composition of a transaminase lowering, it is made up of with weight ratio glucurolactone and Chinese medicine extract at 1: 98, and described Chinese medicine extract is by following method preparation:
With Rhizoma Polygoni Cuspidati 250g, Fructus Gardeniae 200g, Cortex Phellodendri 200g, Herba Reineckeae Carneae 100g, Rhizoma Belamcandae 100g, Radix Sophorae Flavescentis 200g, Radix Salviae Miltiorrhizae 400g decoct with water 3 times, and the 1st time 1.5 hours, the 2nd time 1 hour, the 3rd time 1 hour, merge 3 times decoction liquor, filter, being concentrated into relative density is 1.22-4.25,25 ℃, thick paste.
2. the purposes of compositions as claimed in claim 1 in the medicine of preparation transaminase lowering.
CN2010101740151A 2010-05-11 2010-05-11 Glucuronolactone-containing medicament for protecting liver and lowering transaminase Active CN101843820B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010101740151A CN101843820B (en) 2010-05-11 2010-05-11 Glucuronolactone-containing medicament for protecting liver and lowering transaminase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101740151A CN101843820B (en) 2010-05-11 2010-05-11 Glucuronolactone-containing medicament for protecting liver and lowering transaminase

Publications (2)

Publication Number Publication Date
CN101843820A CN101843820A (en) 2010-09-29
CN101843820B true CN101843820B (en) 2011-08-31

Family

ID=42768758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010101740151A Active CN101843820B (en) 2010-05-11 2010-05-11 Glucuronolactone-containing medicament for protecting liver and lowering transaminase

Country Status (1)

Country Link
CN (1) CN101843820B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413705A (en) * 2002-11-19 2003-04-30 贵州君之堂制药有限公司 Granule for treating hepatopathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1256140C (en) * 2003-12-27 2006-05-17 曾宪寿 Chinese medicne for treating liver cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1413705A (en) * 2002-11-19 2003-04-30 贵州君之堂制药有限公司 Granule for treating hepatopathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
范晓清.《小药治大病：自我用药治疗常见病.《《小药治大病：自我用药治疗常见病》.中原农民出版社 第一版,2007,第91页. *

Also Published As

Publication number Publication date
CN101843820A (en) 2010-09-29

Similar Documents

Publication Publication Date Title
CN101810694B (en) Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis
CN101502551B (en) Synergistic composition containing bifendate
CN100356960C (en) Synergistic medicinal composition for treating hepatitis
CN100421690C (en) Chinese-western medicine composition for treating hepatitis
CN101843820B (en) Glucuronolactone-containing medicament for protecting liver and lowering transaminase
CN100356958C (en) Synergistic medicinal composition for treating hepatitis
CN100363040C (en) Medicinal compositions comprising biphenyldicarboxylate
CN100363045C (en) Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily
CN101837036B (en) Synergetic medicinal composition
CN100353981C (en) Medicine for auxiliary treating hepatitis
CN100393337C (en) Synergistic medicinal composition
CN101810755B (en) Synergism traditional Chinese medicine and western medicine composition containing oleanolic acid
CN100356962C (en) Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate
CN100353978C (en) Synergistic medicinal composition containing tiopronin and Chinese medicine extract
CN100363035C (en) Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract
CN100356961C (en) Synergistic medicinal composition for treating hepatitis
CN100363041C (en) Traditional Chinese medicine and western medicine cooperative compositions comprising biphenyldicarboxylate
CN101502572A (en) Auxiliary Chinese and western medicinal composition for treating hepatitis
CN101837064B (en) Epomediol-containing medicament composition for protecting liver and decreasing enzyme
CN101810759B (en) Curbitacin-containing medicine
CN100450507C (en) Chinese traditional medicine and western medicine composition for treating hepatitis
CN101721597B (en) Pharmaceutical composition containing oleanolic acid
CN101502589B (en) Chinese and western medicinal composition containing bifendate for auxiliary treatment of hepatitis
CN101797337B (en) Medicine containing Guadisu
CN100569253C (en) A kind of medicine of adjuvant treating hepatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LI GUO

Free format text: FORMER OWNER: ZHANG DAYU

Effective date: 20110524

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Li Guo

Inventor after: Zhang Dayu

Inventor before: Zhang Dayu

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100070 BUILDING 18, AREA 8, HEADQUARTER BASE, NO. 188, SOUTH 4TH RING ROAD WEST, FENGTAI DISTRICT, BEIJING TO: 315135 YUNLONG JIAYUAN RESIDENTIAL QUARTER, YUNLONG TOWN, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE

Free format text: CORRECT: INVENTOR; FROM: ZHANG DAYU TO: LI GUO ZHANG DAYU

TA01 Transfer of patent application right

Effective date of registration: 20110524

Address after: 315135 Yunlong District, Yunlong Town, Ningbo, Zhejiang, Yinzhou District

Applicant after: Li Guo

Address before: 100070, No. 18, building eight, 188, base station, South Fourth Ring Road West, Beijing, Fengtai District

Applicant before: Zhang Dayu

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: WANG FENGYU

Free format text: FORMER OWNER: LI GUO

Effective date: 20130218

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 315135 NINGBO, ZHEJIANG PROVINCE TO: 300000 HEXI, TIANJIN

TR01 Transfer of patent right

Effective date of registration: 20130218

Address after: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502

Patentee after: Wang Fengyu

Address before: 315135 Yunlong District, Yunlong Town, Ningbo, Zhejiang, Yinzhou District

Patentee before: Li Guo

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502

Patentee after: Wang Fengyu

Address before: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502

Patentee before: Wang Fengyu

ASS Succession or assignment of patent right

Owner name: HAIAN CHANGDA TECHNOLOGY TRANSFER CENTER CO., LTD.

Free format text: FORMER OWNER: WANG FENGYU

Effective date: 20131218

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 300000 HEXI, TIANJIN TO: 226601 NANTONG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20131218

Address after: 226601 No. 8 Yingbin Road, Haian County, Nantong, Jiangsu

Patentee after: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd.

Address before: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502

Patentee before: Wang Fengyu

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221227

Address after: 413, Floor 4, Building B, Innovation Building, Linyi Hi tech Industrial Development Zone, Shandong Province, 276000

Patentee after: Linyi High tech Zone Jinlanling Labor Service Co.,Ltd.

Address before: No.8 Yingbin Road, Hai'an County, Nantong City, Jiangsu Province

Patentee before: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd.